Arenicin-1 vs Pemvidutide
Head-to-head comparison of Arenicin-1 (Arenicin-1) and Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Arenicin-1 | Pemvidutide |
|---|---|---|
| Category | Marine-Derived | Weight Management |
| Full Name | Arenicin-1 | Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | 2079 Da | N/A |
| Half-Life | n/a | Approximately 1 week |
| Amino Acids | 21 | N/A |
| Typical Dose | n/a | Trial-dependent; once-weekly SC titration |
| Route | preclinical | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 76 | 18 |
| Research Status | Pre-clinical | Clinical |
Arenicin-1 Benefits
- ✓antimicrobial
- ✓anti-biofilm
- ✓membrane-active
Pemvidutide Benefits
- ✓appetite suppression
- ✓body-weight reduction
- ✓improved liver-fat markers
- ✓better glycemic control
Arenicin-1 Dosing
bacterial infection|biofilm disruption
Pemvidutide Dosing
once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose
Arenicin-1 Side Effects
- ⚠Arenicola marina
Pemvidutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Arenicin-1
Marine annelid peptide with strong preclinical antibacterial activity and a stable structural motif that is useful for peptide engineering.
Pemvidutide
Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.